At a glance
ClinicalIndex Comparison RecordN/ACompleted· 62 enrolled
Drug / intervention
Peri-Transfusion QOL Assessmentother
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
PTQA: A New Paradigm of Transfusion Decision Support for Patients With MDS
In Brief
A clinical study evaluating Peri-Transfusion QOL Assessment for Myelodysplastic Syndromes. Completed, enrolled 62 participants across 1 site.
Detailed Summary
This research study is evaluating how to best tailor blood transfusion decisions to match the quality of life changes experienced by individual patients with MDS.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMyelodysplastic Syndromes
CountriesUnited States
CollaboratorsVera and Joseph Dresner Foundation
Timeline
N/ACompletedFinished
20192020202120222023202420252026
First PostedSep 2018
Enrollment StartOct 2018
Primary CompletionJun 2021
TodayJul 2026
First PostedSep 6, 2018
Enrollment StartOct 17, 2018
Primary CompletionJun 30, 2021
TodayJul 2, 2026
Enrollment to primary: 2.7 yearsPosted 7.8 years ago
Interventions
Peri-Transfusion QOL Assessmentother
Participants will undergo a peri-transfusion quality of life assessment (PTQA) using the Quality of Life in Myelodysplasia Scale (QUALMS)